Article Text

Download PDFPDF

251 Targeting HLA-G positive tumors with engineered Natural Killer cells expressing a Chimeric ILT Receptor (CIR)
  1. MyLinh Duong,
  2. Jihyun Park,
  3. Raphael Ognar,
  4. Simon Wain-Hobson and
  5. Henri Bayle
  1. NKILT Therapeutics, Houston, TX, USA


Background CAR-based cell therapies are hampered by a lack of cell surface target proteins that are also good tumor-specific antigens. HLA-G is an exception as it is only highly expressed in cytotrophoblasts of the human placenta where it protects the fetus from all arms of the immune system with very little expression elsewhere. HLA-G directs immunosuppression by binding to ILT receptors (ILT2 in lymphoid cells and ILT4 in myeloid cells) via ITIM signaling domains. HLA-G is derepressed in about 50% of solid tumors and leukemias, notably Acute Myeloid Leukemias (AML).

Methods CD56+ NK cells were selected from PBMCs, incubated with IL-15 and activated with a feeder free cocktail of an immobilized cytokine and activating ligand. Activated NK cells were transduced with γ-retroviruses directing expression of CIR proteins, soluble IL-15 and a ΔCD19 marker protein or CAR control constructs directed to HLA-G or CD33. After 8 days of expansion, CIR- or CAR-NK cells were cocultured with human GFPffluc-expressing AML target cell lines with or without transgenic HLA-G G1, G2 and G5 isoforms. Cytotoxicity of CIR-NK cells was determined by reduction of GFP fluorescence or luciferase activity. In comparative experiments, T cells from PBMCs were transduced to produce CIR-T cells by standard methods.

Results T and NK cells were efficiently and stably transduced by the CIR constructs. In cocultures with THP-1 AML cells (HLA-G negative), mock-transduced NK cells displayed innate killing activity that was not augmented by CIR constructs. In cocultures against THP-1-GFPffluc target cells expressing exogenous G1, G2 or G5 isoforms, CIR-NK cells or CIR-T cells displayed augmented target cell killing in 2-day and 7-day assays relative to mock-transduced effector cells (figure 1). CIR constructs with the two N-terminal domains showed enhanced HLA-G targeting. ILT4 CIR-T cells recognized target cells expressing HLA-G2 that were not recognized by HLA-G CAR-T cells. Further, AML cell lines MOLM13 and Kasumi1 express low endogenous levels of HLA-G1 and G5. In cocultures, CIR-NK cells displayed potent serial killing activity of both cell lines accompanied by secretion of IFN-γ at E:T ratios of 1:10 and 1:20. This anti-tumor efficacy and IFN-γ production were further enhanced in a screen for potent coactivation domains other than 4–1BB that activate innate immunity.

Conclusions This technology takes advantage of the physiological pairing of the ILT receptors with the multiple immunosuppressive HLA-G isoforms. Engineered CIR-NK cells can convert HLA-G expression in AML from a potent inhibitor of lymphocyte activity into a target for anti-tumor control.

Acknowledgements The authors wish to thank Chris Conley and K2 Biosciences (Houston, TX).

Abstract 251 Figure 1

Anti-tumor efficacy of CIR-NK cells in vitro. (A) Schematic depiction of a CIT comprising the extracellular D1 and D2 domains of ILT2, a stalk and transmembrane domain derived from CD8-α and a replacement of the ITIM domains of ILT2 with engineered signalling domains driving NK cell activation. (B,C) 7-day Co-culture of Kasumi1-GFPffluc (B) or Molm13-GFPffluc AML cells with mock-transduced (Mock) NK cells or NK cells transduced to express CIRs containing the D1-D4 extracellular domains (CIR3) or only the D1-D2 domains (CIR4) from ILT2 or ILT4.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.